Premium
Hemodynamic Effects of Intravenous Famotidine in Critically Ill Patients
Author(s) -
Lipsy Robert J.,
Freeman Collin D.
Publication year - 1995
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1995.tb04330.x
Subject(s) - famotidine , critically ill , hemodynamics , medicine , anesthesia , intensive care medicine
Study Objective : To study the hemodynamic effects of famotidine administered undiluted intravenously over 2 minutes. Design : Nonblinded, nonrandomized. Setting : Medical/surgical intensive care unit in a university‐affiliated, tertiary care, teaching hospital. Patients : Eleven consecutive critically ill patients receiving famotidine for stress ulcer prophylaxis. Seven of these patients were also receiving vasopressors or inotropes. Interventions : Famotidine 20 mg/2 ml was administered intravenously undiluted through a peripheral line over 2 minutes. All other medications, including vasopressors and inotropes, were held constant. Measurements and Main Results : No clinically important (> 20 variations from baseline) or statistically significant (p<0.05) changes were seen in heart rate, mean pulmonary arterial pressure, cardiac output, systolic/diastolic blood pressure, systemic vascular resistance, or central venous pressure. Mean arterial pressure (MAP) was elevated at 8 minutes following famotidine (91.2 mm Hg [22.4 SD]) versus baseline (86.7 mm Hg [19.6 SD]). Pulmonary capillary wedge pressure (PCWP) was elevated at 8 minutes (17.2 mm Hg [6 SD]), 12 minutes (17.9 mm Hg [5.68 SD]), and 16 minutes (17.8 mm Hg [6.08 SD]), versus baseline (14.8 mm Hg [7.14 SD]). These changes in MAP and PCWP achieved statistical significance, but were not thought to be of clinical significance. Conclusions : Famotidine given undiluted intravenously over 2 minutes produced no adverse hemodynamic effects in critically ill patients. Administration in this manner should be safe even in patients requiring supportive cardiovascular drug therapy.